HC Wainwright & Co. Reiterates Buy on ATAI Life Sciences, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Patrick Trucchio has reiterated a 'Buy' rating on ATAI Life Sciences (NASDAQ:ATAI) and maintained a $20 price target.
July 10, 2023 | 3:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ATAI Life Sciences has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $20.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates their continued confidence in ATAI Life Sciences. This could potentially lead to increased investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100